Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, May 6, 2021
[ Thu, May 06th 2021
] - WOPRAI
[ Thu, May 06th 2021
] - WOPRAI
[ Thu, May 06th 2021
] - WOPRAI
[ Thu, May 06th 2021
] - WOPRAI
[ Thu, May 06th 2021
] - WOPRAI
[ Thu, May 06th 2021
] - WOPRAI
[ Thu, May 06th 2021
] - WOPRAI
[ Thu, May 06th 2021
] - WOPRAI
[ Thu, May 06th 2021
] - WOPRAI
[ Thu, May 06th 2021
] - WOPRAI
[ Thu, May 06th 2021
] - WOPRAI
[ Thu, May 06th 2021
] - WOPRAI
[ Thu, May 06th 2021
] - WOPRAI
[ Thu, May 06th 2021
] - WOPRAI
[ Thu, May 06th 2021
] - WOPRAI
[ Thu, May 06th 2021
] - WOPRAI
[ Thu, May 06th 2021
] - WOPRAI
[ Thu, May 06th 2021
] - WOPRAI
[ Thu, May 06th 2021
] - WOPRAI
[ Thu, May 06th 2021
] - WOPRAI
[ Thu, May 06th 2021
] - WOPRAI
[ Thu, May 06th 2021
] - WOPRAI
[ Thu, May 06th 2021
] - WOPRAI
[ Thu, May 06th 2021
] - WOPRAI
[ Thu, May 06th 2021
] - WOPRAI
[ Thu, May 06th 2021
] - WOPRAI
[ Thu, May 06th 2021
] - WOPRAI
[ Thu, May 06th 2021
] - WOPRAI
Wed, May 5, 2021
[ Wed, May 05th 2021
] - WOPRAI
[ Wed, May 05th 2021
] - WOPRAI
Geoffrey Porges Maintained (TBPH) at Buy with Decreased Target to $39 on, May 5th, 2021
Geoffrey Porges of SVB Leerink, Maintained "Theravance Biopharma, Inc." (TBPH) at Buy with Decreased Target from $40 to $39 on, May 5th, 2021.
Geoffrey has made no other calls on TBPH in the last 4 months.
There is 1 other peer that has a rating on TBPH. Out of the 1 peers that are also analyzing TBPH, 0 agree with Geoffrey's Rating of Hold.
This is the rating of the analyst that currently disagrees with Geoffrey
- Vikram Purohit of "Morgan Stanley" Maintained at Buy with Decreased Target to $30 on, Monday, March 1st, 2021
